Daniel J. Morgan

Daniel J. Morgan

Auto-generated profile, based on publicly available information

Daniel J. Morgan

Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, West Virginia

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1999 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
ASAlwin G.P. Schuller
Alwin G.P. Schuller
MKMichael A. King
Michael A. King
JZJiwen Zhang
Jiwen Zhang
EBElizabeth Bolan
Elizabeth Bolan
YPYing–Xian Pan
Ying–Xian Pan
JPJohn E. Pintar
John E. Pintar

9 April 2014 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
DMDaniel J. Morgan
Daniel J. Morgan
BDBrian J. Davis
Brian J. Davis
CKChris S. Kearn
Chris S. Kearn
DMDavid Marcus
David Marcus
ACAlex J. Cook
Alex J. Cook
KMKen Mackie
Ken Mackie
For many G-protein-coupled receptors (GPCRs), including cannabinoid receptor 1 (CB1R), desensitization has been proposed as a principal mechanism driving initial tolerance to agonists. GPCR desensitization typically requires phosphorylation by a G-protein-coupled receptor kinase (GRK) and interaction of the phosphorylated receptor with an arrestin. In simple model systems, CB1R is desensitized by GRK phosphorylation at two serine residues (S426 and S430). However, the role of these serine residues in tolerance and dependence for cannabinoidsin vivowas unclear. Therefore, we generated mice where S426 and S430 were mutated to nonphosphorylatable alanines (S426A/S430A). S426A/S430A mutant mice were more sensitive to acutely administered delta-9-tetrahydrocannabinol (Δ9-THC), have delayed tolerance to Δ9-THC, and showed increased dependence for Δ9-THC. S426A/S430A mutants also showed increased responses to elevated levels of endogenous cannabinoids. CB1R desensitization in the periaqueductal gray and spinal cord following 7 d of treatment with Δ9-THC was absent in S426A/S430A mutants. Δ9-THC-induced downregulation of CB1R in the spinal cord was also absent in S426A/S430A mutants. Cultured autaptic hippocampal neurons from S426A/S430A mice showed enhanced endocannabinoid-mediated depolarization-induced suppression of excitation (DSE) and reduced agonist-mediated desensitization of DSE. These results indicate that S426 and S430 play major roles in the acute response to, tolerance to, and dependence on cannabinoids. Additionally, S426A/S430A mice are a novel model for studying pathophysiological processes thought to involve excessive endocannabinoid signaling such as drug addiction and metabolic disease. These mice also validate the approach of mutating GRK phosphorylation sites involved in desensitization as a general means to confer exaggerated signaling to GPCRsin vivo.

24 May 2019 in Drugs
Verified
Journal Article
Closed access
PDF file
HBHenry L. Blanton
Henry L. Blanton
JBJennifer Brelsfoard
Jennifer Brelsfoard
NDNathan DeTurk
Nathan DeTurk
KPKevin Pruitt
Kevin Pruitt
MNMadhusudhanan Narasimhan
Madhusudhanan Narasimhan
JGJosée Guindon
Josée Guindon

1 February 2016 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
AHAngela N. Henderson-Redmond
Angela N. Henderson-Redmond
JGJosée Guindon
Josée Guindon
DMDaniel J. Morgan
Daniel J. Morgan

1 February 1999 in DNA and Cell Biology
Verified
Journal Article
Closed access
YLYinghong Lei
Yinghong Lei
XXXiaonan Xin
Xiaonan Xin
DMDan Morgan
Dan Morgan
JPJohn E. Pintar
John E. Pintar
LFLloyd D. Fricker
Lloyd D. Fricker
The recent finding that Cpe fat/Cpe fat mice, which lack carboxypeptidase E (CPE) activity because of a point mutation, are still capable of a reduced amount of neuroendocrine peptide processing suggested that additional carboxypeptidases (CPs) participate in this processing reaction. Searches for novel members of the CPE gene family led to the discovery of CPD, CPZ, AEBP1, and CPX-2. In the present report, we describe mouse CPX-1, another novel member of this gene family. Like AEBP1 and CPX-2, CPX-1 contains an N-terminal region of 160 amino acids with sequence similarity to the discoidin domain of a variety of proteins. The 410-residue CP-like domain of CPX-1 has 54% to 62% amino acid sequence identity with AEBP1 and CPX-2 and 33% to 49% amino acid identity with other members of the CPE subfamily. However, several active-site residues that are important for catalytic activity of other CPs are not conserved in CPX-1. Furthermore, CPX1 expressed in either the baculovirus system or the mouse AtT-20 cell line does not cleave standard CP substrates. Northern blot analysis showed the highest levels of CPX-1 mRNA in testis and spleen and lower levels in salivary gland, brain, heart, lung, and kidney. In situ hybridization of CPX-1 mRNA in embryonic and fetal mouse tissue showed expression throughout the head and thorax, with abundance in primordial cartilage and skeletal structures. In the head, high levels of CPX-1 mRNA were associated with the nasal mesenchyme, primordial cartilage structures in the ear, and the meninges. In the thorax, CPX-1 mRNA was expressed in multiple developing skeletal structures, including chondrocytes and perichondrial cells of the rib, vertebral, and long-bone primordia. Taken together, these findings suggest that it is unlikely that CPX-1 functions in the processing of neuroendocrine peptides. Instead, CPX-1 may have a role in development, possibly mediating cell interactions via its discoidin domain.

4 May 2010 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
DMDaniel J. Morgan
Daniel J. Morgan
SWSuwen Wei
Suwen Wei
IGIvone Gomes
Ivone Gomes
TCTraci Czyzyk
Traci Czyzyk
NMNino Mzhavia
Nino Mzhavia
JPJohn E. Pintar
John E. Pintar
J. Neurochem. (2010) 113, 1275–1284. Mice with a targeted mutation in proSAAS have been generated to investigate whether peptides derived from this precursor could function as an inhibitor of prohormone convertase 1/3 (PC1/3) in vivo as well as to determine any alternate roles for proSAAS in nervous and endocrine tissues. Fetal mice lacking proSAAS exhibit complete, adult‐like processing of prodynorphin in the prenatal brain instead of the incomplete processing seen in the brains of wild‐type fetal mice where inhibitory proSAAS intermediates are transiently accumulated. This study provides evidence that proSAAS is directly involved in the prenatal regulation of neuropeptide processing in vivo. However, adult mice lacking proSAAS have normal levels of all peptides detected using a peptidomics approach, suggesting that PC1/3 activity is not affected by the absence of proSAAS in adult mice. ProSAAS knockout mice exhibit decreased locomotion and a male‐specific 10–15% decrease in body weight, but maintain normal fasting blood glucose levels and are able to efficiently clear glucose from the blood in response to a glucose challenge. This work suggests that proSAAS‐derived peptides can inhibit PC1/3 in embryonic brain, but in the adult brain proSAAS peptides may function as neuropeptides that regulate body weight and potentially other behaviors.